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Abstract
Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical 
extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were 
reviewed to identify 1265 patients who underwent cryoablation (CA) or radiofrequency ablation (RFA) for enhancing renal masses. Disease per-
sistence or recurrence was classified into one of the three categories: (i) residual disease in ablation zone; (ii) recurrence in the ipsilateral renal unit; 
and (iii) metastatic/extra-renal disease. Seventy seven patients (6.1%) had radiographic evidence of disease persistence or recurrence at a median 
interval of 13.7 months (range, 1–65 months) post-ablation. Distribution of disease included 47 patients with residual disease in ablation zone, 29 
with ipsilateral renal unit recurrences (all in ablation zone), and one with metastatic disease. Fourteen patients (18%) elected for surveillance, and 
the remaining underwent salvage ablation (n = 50), partial nephrectomy (n = 5), or radical nephrectomy (n = 8). Salvage ablation was successful 
in 38/50 (76%) patients, with 12 failures managed by observation (3), tertiary ablation (6), and radical nephrectomy (3). At a median follow-up of 
28 months, the actuarial cancer-specific survival and overall survival in this select cohort of patients was 94.8 and 89.6%, respectively.
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Introduction
The widespread use of abdominal cross-sectional imaging 
has contributed to the observed increased incidence and 
detection of small renal masses (SRMs) (1, 2). The major-
ity of incidentally found SRMs are pathologically renal cell 
carcinomas (RCC) albeit with variable clinical behavior (3). 
Although the rates of RCC are increasing at 2–3% annually 
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Treatment failure was classified into one of three catego-
ries. Disease persistence or incomplete primary ablation was 
characterized by radiographic or biopsy evidence of viable 
carcinoma in the ablation zone on the initial radiographic 
study performed following the procedure (approximately ≤ 3 
months). Recurrence in the ipsilateral renal unit was defined 
as evidence of carcinoma either in the ablation zone or 
within the ipsilateral kidney (by imaging or biopsy), follow-
ing an initial negative imaging study. Metastatic or distant 
disease was characterized as evidence of RCC at a site out-
side of either renal unit.
Results
Between August 2010 and March 2015, 1265 patients under-
went ablation for renal cortical neoplasms at nine centers. 
Eight hundred and seventy five patients (69%) underwent 
RFA (683 percutaneous, 192 laparoscopic) and 390 patients 
(31%) underwent CA (183 laparoscopic, 207 percutaneous). 
Treatment approach was nonstandardized and was at the 
discretion of individual institutions and urologists. How-
ever, hilar tumors were generally managed laparoscopically 
to permit mobilization of the medial structures, including 
the colon, duodenum, and pancreas. Furthermore, the lap-
aroscopic approach permitted identification of the hilar 
vessels, thereby minimizing the risk of  procedural bleeding. 
All treatment approaches were performed collaboratively 
between urologists and interventional radiologists, with 
laparoscopic procedures completed by urologists and percu-
taneous procedures completed by both urologists and inter-
ventional radiologists.
Overall, 77 patients (6.1%) had evidence of disease per-
sistence or recurrence at a mean interval of 13.7 months 
(range, 1–65 months), following ablation. Specifically, in 
those who underwent RFA, 6.6% experienced an oncologic 
recurrence (58/875), and in patients undergoing CA, 4.9% 
developed a recurrence (19/390). Of these, 21 were biopsied 
and all were positive for RCC. Table 1 highlights the charac-
teristics of tumors with evidence of radiographic persistence 
or recurrence.
Amongst those with ablation failure, 47 (61%) were clas-
sified as disease persistence (incomplete ablation) in the 
treatment zone; 29 (38%) as ipsilateral renal recurrence, 
all of which were in the primary ablation zone; and one 
(1%) with metastatic disease to the lung. Ipsilateral renal 
ablation zone recurrences were detected at a mean of 20.3 
months (range, 4–59), following primary ablation. There 
were no differences in recurrence rates between percutaneous 
(56/890, 6.3%) and laparoscopic (21/375, 5.6%) approaches 
(P = 0.24). In addition, on further subgroup analysis, per-
cutaneous RFA (49/683, 7.2%) had a higher recurrence rate, 
compared to percutaneous CA (7/207, 3.4%) (P = 0.05), but 
no other differences between any of the other subgroups, 
worldwide, most of these cancers are localized and accord-
ingly are highly treatable with excellent disease-specific 
survival (4). The American Urologic Association (AUA) 
guidelines highlight the standard of care for the management 
of SRMs, including partial or radical nephrectomy when 
feasible, with surveillance and thermal ablation as appropri-
ate in certain patient cohorts (5). Results of thermal ablation 
in appropriately selected patients can be comparable with 
surgical extirpation (6).
Incorporation of renal tumor ablation into clinical prac-
tice requires an understanding of the incidence and patterns 
of recurrence, which can occur in up to 20% of patients, 
depending on tumor characteristics (7). In general, if  disease 
persistence or recurrence occurs, it typically manifests within 
the first few months following initial ablative  therapy  (8). 
Several options have been proposed for the management of 
a failed ablative procedure, including surveillance, salvage 
ablation, and partial and radical nephrectomies (9, 10). Sal-
vage ablation, in particular for locally recurring RCC fol-
lowing cryoablation (CA), has been shown to be a feasible 
option with good outcomes and low complication rates (11).
When renal tumors are appropriately selected for thermal 
ablation, the likelihood of disease persistence or recurrence 
is low. Therefore, there is a relative paucity of information 
regarding specific management strategies to address residual 
or recurrent disease following renal thermal ablation. To this 
end, we reviewed a large multicenter database of patients 
with failed renal ablation to highlight subsequent manage-
ment strategies.
Patients and Methods
Following Institutional Review Board (IRB) approval at 
each of the participating institutions, a review of prospec-
tively maintained institutional databases identified patients 
who underwent renal thermal ablation by either CA or 
radiofrequency ablation (RFA). Ablation was performed by 
either laparoscopic or percutaneous approaches, which were 
dependent on tumor size, configuration, and proximity to 
adjacent structures. Clinical records reviewed included office 
notes, operative reports, pathology and imaging data that 
identified those patients with oncologic recurrence following 
ablative therapy.
The primary outcome variables included evidence of renal 
oncologic recurrence and its subsequent management. Axial 
cross-sectional imaging studies with and without contrast 
were reviewed to identify disease recurrence. Specifically, the 
presence of contrast enhancement or lesion growth in the 
ipsilateral renal unit, including the ablation zone, was con-
sidered as evidence of radiographic local treatment failure. 
For those patients unable to receive contrast-based studies, 
evidence of residual or recurrent disease was confirmed by 
percutaneous renal mass biopsy (RMB).
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including laparoscopic RFA (9/192, 4.7%) and laparoscopic 
CA (12/183, 6.6%), were observed (P = 0.19).
Figure 1 highlights the management strategies employed in 
those experiencing disease persistence or recurrence follow-
ing RFA or CA. Of the 77 patients, 14 chose surveillance, 
50 underwent secondary salvage ablation, and a total of 13 
underwent extirpative surgery (five partial, eight radical). 
The patient experiencing metastasis had an 8.4-cm clear-
cell carcinoma in a solitary kidney with medical comorbid-
ities. This patient developed pulmonary metastasis 7 months 
post-procedure managed by surveillance due to competing 
medical issues. In the cohort that proceeded with salvage 
ablation, a successful salvage procedure was documented in 
38 patients, whereas 12 patients experienced recurrence after 
salvage ablation. In these 12 patients with a second post- 
salvage ablation recurrence, three underwent surveillance, 
six underwent a repeat tertiary salvage ablation, and three 
proceeded with radical nephrectomy. In the six patients who 
underwent tertiary salvage ablation, three experienced a suc-
cessful procedure, whereas three developed a recurrence and 
subsequently elected for surveillance. The final pathology 
for the 16 patients who eventually underwent surgical extir-
pation was RCC in 11, necrosis/fibrosis in four, and oncocy-
toma in one.
Table 1: Pre-treatment radiographic and pathologic charac-
teristics of 77 renal tumors managed by ablation, with sub-
sequent evidence of disease persistence or recurrence.
Size (cm; median, range) 3.1 (1.5–8.4)
Histologic subtype (No., %)
Clear Cell
Papillary
Chromophobe
Benign
Nondiagnostic
51 (66)
13 (17)
2 (3)
3 (4)
8 (10)
Nuclear grade (No., %)*
Low
High
Unspecified
23 (35)
32 (48)
11 (17)
Nephrometry score  6 (4 – 9)
Posterior (No., %) 46 (60)
Hilar (No., %) 6 (8)
Solitary kidney (No., %) 9 (12)
Biopsy confirmed recurrence (No., %) 21 (27)
*percentage based only on histology of cancer cases (n = 66).
Ablation recurrences
(n=77)
Surveillance
(n=14)
Surveillance
(n=3)
Salvage ablation
(n=50)
Successful salvage ablation
(n=38)
Successful repeat
salvage ablation
(n=3)
Repeat
salvage ablation
(n=6)
Recurrence after salvage ablation
(n=12)
Recurrence on
surveillance
(n=3)
Partial nephrectomy
(n=5)
Radical nephrectomy
(n=8)
Radical nephrectomy
(n=3)
Figure 1: Management of disease persistence or recurrence following primary renal tumor ablation.
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Overall, at a median follow-up of 28 months, the cancer- 
specific survival and overall survival in this select cohort 
of patients with ablation failure was 94.8 and 89.6%, 
respectively.
Discussion
The goal of this study was to use a large, multicenter renal 
thermal ablation dataset to specifically evaluate the rates of 
treatment failure and subsequent management strategies. 
Our observations noted that renal ablation carried out at 
high-volume centers demonstrates low treatment failure rates 
(~ 6%), with greater than 60% being attributable to incom-
plete primary ablation. Surveillance, salvage ablation, and 
surgical extirpation were all management options incorpo-
rated in practice with excellent cancer-specific survival and 
overall survival. These data are quite encouraging in pre-
senting a framework for managing failures after renal abla-
tive therapy, with enhanced patient counseling prior to the 
procedure.
Ablative therapies present a treatment option that can 
be successfully employed when managing a patient with an 
SRM (5). Indeed, early data from high-volume centers of 
excellence highlight favorable oncologic outcomes with a rel-
atively low morbidity rate. In particular, Weld and colleagues 
highlighted in a summary of a published series that 4.6% 
of patients who underwent CA and 7.9% of patients who 
underwent RFA experienced a recurrence (12). Notably, our 
study, which represents some of the highest case numbers 
reported, demonstrated a similar recurrence rate of 6.1%, 
with only one patient experiencing a metastatic recurrence. 
The metastatic event was not entirely surprising given the 
challenging scenario of managing a cT2 renal mass in a med-
ically comorbid patient with a solitary kidney.
Nonetheless, it is important to recognize that a percentage 
of patients undergoing renal ablation will invariably experi-
ence a treatment failure that requires subsequent manage-
ment. In that regard, there is a relative paucity of literature 
delving into management options and outcomes following a 
failed renal ablation therapy. Breda et al. conducted a sys-
tematic review to identify renal ablation therapy cases and to 
provide an overview of treatment options in those experienc-
ing recurrence. They demonstrated that for tumor recurrence 
following renal ablation, viable treatment options include 
active surveillance, repeat ablation, and salvage nephrectomy. 
Specifically, for patients with early enhancement (which may 
be attributed to postoperative inflammation), active surveil-
lance of up to 1-year stands as a fairly reliable option and 
may prevent unnecessary therapy in those whose disease has 
been effectively managed (9). Similarly, Okhunov and col-
leagues demonstrated excellent results for salvage CA of T1a 
RCC in a smaller multicenter report (11). Our study similarly 
noted that while 18% of our patients elected for surveillance 
of suspected residual or recurrent disease, a similar propor-
tion (20%) ultimately required extirpative salvage surgery.
Similar observations from Matin et al. noted that RFA 
patients had a 13.4% risk of residual or recurrent disease and 
CA patients had a 3.9% risk of treatment failure, following 
primary renal thermal ablation. These authors recorded a 
rather low therapy failure of 4.2% in those undergoing sal-
vage ablative therapy, and for the population with recurrent 
disease, they documented an overall survival rate of 82.5% 
and a 2-year metastasis-free survival rate of 97.4% in those 
with localized, unilateral tumors. Akin to our study, a major-
ity of recurrences were detected within the first 3 months fol-
lowing treatment (8).
It is important to recognize that ablation is most success-
ful in the initial attempt and patients must be aware that sal-
vage ablative procedures are (in general) likely to yield lower 
success rates. Indeed, in our series, the treatment failure rate 
of primary ablation was ~6%, secondary ablation was ~25%, 
and tertiary ablation was ~50%. Furthermore, our data sug-
gest the potential value of RMB to better guide treatment 
in those patients with suspected recurrence. The absence of 
enhancement on contrast-based studies has been shown to be 
reliable in excluding viable carcinoma in ablated tumors (13). 
However, the presence of enhancement, particularly weak 
contrast uptake, is not pathognomonic for residual or recur-
rent disease and may represent inflammatory changes (14). 
Our results highlight that of those patients undergoing extir-
pative surgery, 25% had only necrosis or fibrosis on final 
pathology. In such patients, RMB may certainly guide a 
 priori the subsequent need for therapy (15).
Newer techniques such as stereotactic ablative radio-
surgery for renal cortical tumors may also certainly play a 
role in the primary or salvage treatments. A recent pooled 
analysis from the International Radiosurgery Oncology 
Consortium for Kidney (IROCK) underscored the impor-
tance of this treatment approach (16). Of 223 patients in this 
series, the rates of local control, cancer-specific survival, and 
progression- free survival were 97.8, 95.7, and 77.4%, respec-
tively, at 2 years; and they were 97.8, 91.9, and 65.4%, respec-
tively, at 4 years. Such data highlight the promise of ablative 
options that are potentially even less invasive.
We acknowledge that this study is not without limitations. 
Our findings are limited by the study’s small sample size and 
its retrospective nature, and therefore treatment algorithms 
and strategies were at the discretion of individual clinicians. 
Furthermore, all tumors were not biopsied prior to manage-
ment and therefore the treatment success and failure rates 
were based on treating enhancing SRMs some of which may 
not be pathologically kidney cancer. In addition, pathologic 
information and radiographic characteristics of the entire 
cohort of treated patients (n = 1265) were not available to 
determine factors predictive for disease recurrence. Nonethe-
less, we believe our data offer large-scale insight into specific 
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patterns of treatment and outcomes in those with residual or 
recurring disease following renal ablation.
Conclusions
Oncologic recurrence is an important consideration in 
patients undergoing ablation therapy for renal masses. For 
those experiencing a recurrence, there are several manage-
ment strategies that can be employed for disease control. 
Careful delineation of algorithms for residual or recurring 
disease permits optimized patient counseling prior to pri-
mary ablation therapy. Experience and lesion selection may 
play an important role in guiding successful ablation.
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